Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725776 | SCV000339307 | pathogenic | not provided | 2017-07-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000341255 | SCV000649771 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 137 of the SGCA protein (p.Glu137Lys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with limb-girdle muscular dystrophy (LGMD) (PMID: 9192266, 12075495, 19798725, 25214167, 26916285). ClinVar contains an entry for this variant (Variation ID: 286049). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SGCA protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects SGCA function (PMID: 22095924). This variant disrupts the p.Glu137 amino acid residue in SGCA. Other variant(s) that disrupt this residue have been observed in individuals with SGCA-related conditions (PMID: 28403181), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Centre for Mendelian Genomics, |
RCV000341255 | SCV001367738 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2016-01-01 | criteria provided, single submitter | clinical testing | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM1,PM2,PP3. This variant was detected in homozygous state. |
Revvity Omics, |
RCV000341255 | SCV003825579 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-05-26 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000341255 | SCV003931668 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000725776 | SCV004168957 | pathogenic | not provided | 2023-05-04 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 34426522, 31589614, 22095924, 9192266, 30703231, 21031578, 30764848, 16778590, 31069529, 12075495, 18285821, 25214167, 31980526, 19798725, 26916285, 24077912, 30107846) |
Baylor Genetics | RCV000341255 | SCV004203165 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2024-03-27 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000341255 | SCV000789139 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2017-01-10 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000341255 | SCV001453379 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2020-09-16 | no assertion criteria provided | clinical testing |